Magali Provansal
Overview
Explore the profile of Magali Provansal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vicier C, Sfumato P, Isambert N, Dalenc F, Robert M, Levy C, et al.
Eur J Cancer
. 2021 Nov;
159:205-214.
PMID: 34781168
Background: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC...
12.
Tredan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, Hardy-Bessard A, Kalbacher E, et al.
Gynecol Oncol
. 2021 Oct;
164(1):18-26.
PMID: 34696892
Objective: To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression....
13.
Rousset-Rouviere S, Rochigneux P, Chretien A, Fattori S, Gorvel L, Provansal M, et al.
Biomedicines
. 2021 Jul;
9(6).
PMID: 34199461
Endometrial cancer (EC) can easily be cured when diagnosed at an early stage. However, advanced and metastatic EC is a common disease, affecting more than 15,000 patients per year in...
14.
Bertucci F, Goncalves A, Guille A, Adelaide J, Garnier S, Carbuccia N, et al.
Genome Med
. 2021 May;
13(1):87.
PMID: 34006291
Background: The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults with advanced...
15.
Marino P, Touzani R, Seguin L, Moulin J, Palomares M, Cappiello M, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809577
Patient satisfaction is linked to the amount of time spent with the physician. At the same time, long waiting times in hospitals are a major source of patient dissatisfaction. The...
16.
Sabatier R, Martin J, Vicier C, Guerin M, Monneur A, Provansal M, et al.
J Clin Med
. 2021 Apr;
10(6).
PMID: 33803894
Patients And Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the...
17.
Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, et al.
JAMA Oncol
. 2020 Oct;
6(12):1923-1930.
PMID: 33030515
Importance: To our knowledge, this is the first randomized trial in sex cord-stromal tumors, and it establishes weekly paclitaxel as standard-of-care therapy after platinum-based therapy in this setting. Objective: To...
18.
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux E, et al.
Gynecol Oncol
. 2020 Jul;
159(1):129-135.
PMID: 32723678
Purpose: Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is a rare and rapidly lethal disease affecting young women. Cytoreductive surgery associated with chemotherapy followed by a high...
19.
Selle F, Heudel P, Hardy-Bessard A, Pozet A, Meunier J, Gladieff L, et al.
Anticancer Res
. 2020 Jul;
40(7):3939-3945.
PMID: 32620635
Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional...
20.
Chevrot A, Pouget N, Bats A, Huchon C, Guyon F, Chopin N, et al.
Gynecol Oncol
. 2020 Apr;
157(1):29-35.
PMID: 32241341
Objectives: Description of fertility and prognosis of patients with borderline ovarian tumor (BOT) treated by fertility-sparing surgery through a longitudinal study from the French national cancer network. Methods: All consecutive...